检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:刘涛峰[1] 张虹亚[1] 刘小平[1] 严静[1] 孙洪波[1] 吴敏[1] 王建锋[1]
机构地区:[1]安徽省中医院皮肤性病科,安徽合肥230031
出 处:《中国皮肤性病学杂志》2012年第5期442-444,共3页The Chinese Journal of Dermatovenereology
基 金:安徽省卫生厅中医药课题(2009ZY24)
摘 要:目的观察复方泽漆冲剂对血热、血瘀、血燥三型寻常性银屑病(PV)患者血清中IL-17,IL-22和IL-23的影响,探讨复方泽漆冲剂对三型PV患者IL-23/Th17细胞轴的影响。方法三型PV患者均口服复方泽漆冲剂,每型患者均为20例,疗程4周,采用ELISA法对60例PV患者治疗前后和10例健康对照组的血清中IL-17,IL-22和IL-23水平进行检测。结果 60例PV患者血清中的IL-17,IL-22和IL-23的水平治疗前、后均明显高于健康对照组(P均<0.01)。三型患者治疗后的IL-17,IL-22和IL-23的水平与治疗前相比,均明显下降,(P均<0.01)。血热型治疗前、后的IL-17,IL-22和IL-23分别为23.369±2.402pg/mL,12.753±2.014pg/mL;200.694±20.087pg/mL,135.772±10.551pg/mL;23.124±1.886pg/mL,16.156±2.481pg/mL。血瘀型治疗前后的IL-17,IL-22和IL-23分别为23.456±2.142pg/mL,14.944±1.912pg/mL;200.554±19.725pg/mL、146.112±16.523pg/mL;22.562±1.768pg/mL,14.512±2.111pg/mL。血燥型治疗前后的IL-17,IL-22和IL-23分别为24.556±1.653pg/mL,16.836±2.161pg/mL;204.754±19.428pg/mL,155.702±11.489pg/mL;23.362±2.462pg/mL、12.876±2.462pg/mL。结论复方泽漆冲剂能降低三型PV患者血清中IL-17,IL-22和IL-23的水平,其中对血热型的作用最强,对血瘀型次之,对血燥型最弱。Objective Through the observation of ZeQi Granule influence on IL-17,IL-22,IL-23 on blood heat, blood stasis, blood dryness three types of PV patients, ZeQi Granule treatment on diffentent TCM syn- drome types of PV patients influences on IL-23/Th17 cell axis. Methods Three types of PV patients are all on Ze Qi Granule per oral for four weeks. Each type involves 20 patients.Levels of IL-17,IL-22,IL- 23 in serum of 60patients with PV before and after treatment., and 10 heathy persons as controls were de- tected by ELISA. Results Serum IL-17, IL-22, IL-23 of 60 PV patients were significantly higher thanhealthy controls(P〈0.01). After treatment the levels of IL-17, IL-22, IL-23 in three types of PV patients were significantly lower than before and are all P〈0.01. Serum IL-17, IL-22, IL-23 of blood heat patients before and after treatment respectively are 23.369±2.402 pg/mL, 12.753±2.014 pg/mL;200.694±20.087 pg/ mL,135.772±10.551 pg/mL;23.124±l.886 pg/mL,16.156±2.481 pg/mL. Serum IL-17, IL-22, IL-23 ofblood stasis patients before and after treatment respectively are 23.456±2.142 pg/mL, 14.944±1.912 pg/mL; 200.554±19.725 pg/mL, 146.112±16.523 pg/mL;22.562±l.768 pg/mL, 14.512±2.111 pg/mLo Serum IL-17, IL-22, IL-23 of blood dryness patients before and after treatment respectively are24.556±l.653 pg/ml,16.836±2.161 pg/rnL;204.754±19.428 pg/mL, 155.702±11.489 pg/mL;23.362±2.462 pg/mL. 12.876±2.462 pg/ mL. Conclusion ZeQi granule can decrease serum IL-17, IL-22, IL-23 of three types of PV patients, The effect on blood heat type is the strongest, followed by the blood stasis type, and the last blood dryness type.
分 类 号:R758.63[医药卫生—皮肤病学与性病学]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.145